-
Digoxin: From Ion Pumps to Translational Strategy
2026-09-10
Digoxin is more than a cardiac glycoside: it is a mechanistically defined Na+/K+ ATPase pump inhibitor that connects ion transport, cardiac contractility modulation, and cell-context-dependent antiviral research. This thought-leadership article examines how to translate Digoxin from arrhythmia treatment research and congestive heart failure animal models into disciplined CHIKV assay design, while defining the boundaries that prevent overinterpretation.
-
BCS Biowaivers for Taltirelin ODTs and IR Formulations
2026-09-10
The reference study experimentally examined whether dissolution testing could support BCS-based biowaivers for orally disintegrating tablets compared with immediate-release formulations. Its findings identify Taltirelin as a BCS class III example with very rapid dissolution and show why dose-to-solubility ratio remains important when interpreting formulation equivalence.
-
Ridaforolimus: From mTOR Signal to Assay Decision
2026-09-09
Ridaforolimus (Deforolimus) is a potent mTOR-pathway probe for connecting signaling changes with proliferation, apoptosis, angiogenesis, and senescence-related phenotypes. This guide presents a phenotype-first assay strategy grounded in machine-learning-enabled senolytic discovery.
-
Uridine, Trisodium Salt for RNA Workflows
2026-09-09
Uridine, Trisodium Salt supports controlled RNA metabolism, cellular biosynthesis, and vascular response experiments when researchers distinguish nucleoside feeding from direct in vitro transcription. This guide connects high-purity reagent handling with RNA-mediated genome-engineering workflows inspired by PRINT, while emphasizing assay controls and troubleshooting.
-
Topotecan and Replication Stress: A Translational Playbook
2026-09-08
Topotecan is more than a cytotoxic agent: it is a mechanistic probe for replication-fork vulnerability, DNA repair dependence, and translational model selection. This thought-leadership guide connects Topotecan or SKF104864 exposure to Dna2 biology, glioma assays, pediatric tumor models, and clinically relevant combination strategies.
-
Romidepsin (FK228) Research Workflows
2026-09-07
Build reproducible HDAC1/2 inhibition workflows with Romidepsin (FK228), from solvent handling and 72-hour viability assays to apoptosis, chromatin, and proteomics readouts. The approach also shows how a recent RFC4–Notch study can inform orthogonal assay selection without overstating mechanistic overlap.
-
Coronavirus Macrodomain Restrains PARP Antiviral Activity
2026-09-07
Grunewald and colleagues showed that coronavirus macrodomains counter host PARP-dependent ADP-ribosylation, thereby preserving viral replication while limiting interferon induction. Using mutant and wild-type viruses, pharmacological inhibition, and PARP12 or PARP14 knockdown, the study identifies a mechanistic link between viral macrodomain activity and innate immune regulation.
-
AZD8055: Practical mTOR Inhibitor Workflow
2026-09-05
AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling, cancer cell proliferation, and metabolism. This dossier-based guide covers preparation, assay setup, QC, and interpretation, but the compound should not be used as a substitute for clinical efficacy evidence or model-specific optimization.
-
MEHP, AhR, and Ovarian Follicle Toxicity
2026-09-05
This study identifies aryl hydrocarbon receptor activation as a functional mediator of mono(2-ethylhexyl) phthalate toxicity in mouse ovarian antral follicles. By combining MEHP exposure with pharmacological AhR inhibition, the authors connect impaired follicle growth, reduced estrogen production, and altered estrogen-responsive gene expression within a single experimental framework.
-
Naloxone Hydrochloride Research Workflows
2026-09-04
Build more informative opioid assays with Naloxone hydrochloride, from receptor-blockade and withdrawal models to neural stem cell proliferation modulation. This guide combines product handling, reference-informed behavioral design, cross-domain applications, and troubleshooting for more reproducible research.
-
Bsa I (RNase-free): Practical DNA Workflow
2026-09-04
Bsa I (RNase-free) supports sequence-directed DNA cleavage for gene cloning, DNA manipulation, and other molecular biology research workflows where RNA contamination should be minimized. This guide covers product-specific parameters and practical setup controls; the enzyme is for scientific research only and not for diagnostic, clinical, or medical use.
-
TP53, ATM, and MDM2 Shape Calicheamicin ADC Response
2026-09-03
This study used genome-wide CRISPR/Cas9 screening and comparative leukemia models to identify TP53, ATM, and MDM2 as important regulators of sensitivity to calicheamicin, the payload shared by gemtuzumab ozogamicin and inotuzumab ozogamicin. Its results clarify why DNA-damaging antibody–drug conjugates can fail in acute leukemia and support rational testing of p53- and ATM-directed combinations, while arguing against a generalized benefit from PARP inhibition in this setting.
-
Doxorubicin and Persister-Cell Ferroptosis
2026-09-02
Doxorubicin, also known as Adriamycin, is more than a DNA-damaging reference compound. This article explains how to use its treatment pressure to investigate reversible persister states, lipid remodeling, mitochondrial dependence, and ferroptosis sensitivity in cancer models.
-
Taltirelin acetate: Reliable Assay Workflows
2026-09-02
A scenario-based guide to using Taltirelin acetate in neuronal viability, neuroprotection, formulation, and translational research workflows. It explains how SKU C8755 can support controlled dosing, practical stock preparation, and more defensible interpretation of assay results.
-
Flubendazole Workflows for Autophagy Research
2026-09-02
Flubendazole supports controlled autophagy modulation research when formulation, exposure time, and cell-killing readouts are planned together. This workflow translates evidence from cancer-response research into practical assay design, helping distinguish growth arrest from true cytotoxicity.